Firebrick Pharma (ASX:FRE) founder and CEO Peter Molloy addressed investors this week around commercialisation of Nasodine, a nasal spray that kills cold and flu viruses without any potential for resistance.
The product developed from PVP-iodine (the same active ingredient in the antiseptic brand Betadine) and is available to Australians online.
Firebrick is already establishing other markets in the US, Singapore, Fiji, South Pacific and the Philippines.
Dr Molloy – who launched Betadine in Australia – speaks about how the human mindset has changed in relation to viruses since COVID. He says there’s also widespread fear of future pandemics.
“We’re on a quest,” he says.
“We have a moral, ethical obligation to make Nasodine available worldwide.”
Firebrick Pharma is a pharmaceutical developer focused on developing and commercialising novel formulations and uses of povidone-iodine.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。